Zeiher Bernhardt G 4
4 · Entrada Therapeutics, Inc. · Filed May 21, 2026
Research Summary
AI-generated summary of this filing
Entrada Therapeutics (TRDA) Director Bernhardt G. Zeiher Buys 5,000 Shares
What Happened
Bernhardt G. Zeiher, a director of Entrada Therapeutics (TRDA), purchased 5,000 shares in open-market transactions on 2026-05-20. The Form 4 reports a weighted-average price of $5.86 per share for a total reported outlay of $29,316. This was a purchase (insider buy), not a sale.
Key Details
- Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (filed within the standard two-business-day reporting window).
- Price reported (weighted average): $5.86 per share; total reported value: $29,316.
- Footnote F1: The $5.86 is a weighted average; the shares were bought in multiple trades at prices ranging from $5.86 to $6.00. The reporting person can provide a breakdown on request.
- Footnote F2: The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest; this filing should not be interpreted as an admission of beneficial ownership under Section 16.
- Shares owned after the transaction: not disclosed in the provided Form 4.
Context
This was an open-market purchase (transaction code P) executed across multiple trades. Purchases by directors can be of interest to retail investors because they show the insider putting personal funds into the stock; this particular buy was relatively small (~$29k). The filing appears timely and includes a note that the reported price is a weighted average across several trades.
Insider Transaction Report
- Purchase
Common Stock
[F1][F2]2026-05-20$5.86/sh+5,000$29,316→ 5,000 total(indirect: By Trust)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.86 to $6.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.